FDAsafety guidance72% confidence
FDA AP — CHILDREN'S ALLEGRA HIVES (SUPPL)
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Sanofi.
Regulatory Analysis
Application NDA021909. Sponsor: CHATTEM SANOFI. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: FEXOFENADINE HYDROCHLORIDE.
Supporting Context
- Therapeutic area
- Infectious Disease · Respiratory Syncytial Virus (RSV)
- Sub-indication
- General
Related signal: Sanofi's Nirsevimab Study to Assess RSV Immunisation Rates in Queensland Infants